Abstract
Background Preparations from Echinacea are among the best-selling phytopharmaceuticals worldwide and have been widely used for the treatment of common cold and various upper respiratory infections. The most relevant active principles of Echinacea extracts are alkamides, caffeic acid derivatives (CADs) and glycoproteins/polysaccharides [1]. The main alkamides in Echinacea preparations are the isomeric dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (''tetraenes''). Until now, a limited number of pharmacokinetic studies with alkamides have been reported, but no data exist about their distribution in tissues and transport through the blood-brain barrier (BBB). Therefore, we evaluated the pharmacokinetics of dodeca-2E,4E,8E,10E/Ztetraenoic acid isobutylamides after a single oral dose administration of 2.5 mg/kg in plasma as well as in liver and four different brain regions (hippocampus, cerebral cortex, striatum and cerebellum).
Highlights
Preparations from Echinacea are among the best-selling phytopharmaceuticals worldwide and have been widely used for the treatment of common cold and various upper respiratory infections
A limited number of pharmacokinetic studies with alkamides have been reported, but no data exist about their distribution in tissues and transport through the blood-brain barrier (BBB)
We evaluated the pharmacokinetics of dodeca-2E,4E,8E,10E/Ztetraenoic acid isobutylamides after a single oral dose administration of 2.5 mg/kg in plasma as well as in liver and four different brain regions
Summary
Preparations from Echinacea are among the best-selling phytopharmaceuticals worldwide and have been widely used for the treatment of common cold and various upper respiratory infections. The most relevant active principles of Echinacea extracts are alkamides, caffeic acid derivatives (CADs) and glycoproteins/polysaccharides [1]. The main alkamides in Echinacea preparations are the isomeric dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (''tetraenes''). A limited number of pharmacokinetic studies with alkamides have been reported, but no data exist about their distribution in tissues and transport through the blood-brain barrier (BBB). We evaluated the pharmacokinetics of dodeca-2E,4E,8E,10E/Ztetraenoic acid isobutylamides after a single oral dose administration of 2.5 mg/kg in plasma as well as in liver and four different brain regions (hippocampus, cerebral cortex, striatum and cerebellum)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
